Chimeric: Media Thread, page-888

Another article on Satri Cel, a CART therapy targeting claudin 18.2 on gastric cancer.

just completed enrolment of phase 2 pivotal trial.

CHM CDH17 groundbreaking study has strong parallels to Satie Cel but important differences:

a) CDH17 targets a different protein (CDH17) which is more common than claudin 18.2
b) CDH17 trial is a phase 1/2 such that the company can immediately move to phase 2 (potentially registrational) after proving safe and showing some efficacy in phase 1



https://www.prnewswire.com/news-releases/carsgen-announces-enrollment-completion-in-china-gcgej-pivotal-phase-ii-clinical-trial-of-the-first-in-class-claudin18-2-car-t-satri-cel-302225000.html